dalteparin has been researched along with Cerebral Ischemia in 50 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study showed no superiority of low-molecular-weight heparin (LMWH) over aspirin for the primary end point (Barthel Index) in acute ischemic stroke due to large artery occlusive disease." | 9.16 | Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study. ( Chen, C; Chen, XY; Han, JH; Leung, TW; Mok, V; Soo, Y; Wang, QS; Wong, KS, 2012) |
| "Heparin in Acute Embolic Stroke Trial (HAEST) was a multicentre, randomised, double-blind, and double-dummy trial on the effect of low-molecular-weight heparin (LMWH, dalteparin 100 IU/kg subcutaneously twice a day) or aspirin (160 mg every day) for the treatment of 449 patients with acute ischaemic stroke and atrial fibrillation." | 9.09 | Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000) |
| "We evaluated the efficacy of low-molecular-weight heparin (LMWH) relative to aspirin in preventing early neurologic deterioration (END), venous thromboembolism (VTE), and outcomes at 6 months." | 5.19 | Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deterioration and improving six-month outcome. ( Chi, W; Lin, J; Wang, C; Yi, X; Zhang, B, 2014) |
| "The Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study showed no superiority of low-molecular-weight heparin (LMWH) over aspirin for the primary end point (Barthel Index) in acute ischemic stroke due to large artery occlusive disease." | 5.16 | Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study. ( Chen, C; Chen, XY; Han, JH; Leung, TW; Mok, V; Soo, Y; Wang, QS; Wong, KS, 2012) |
| "TAIST was a randomized controlled trial assessing 10 days of treatment with tinzaparin versus aspirin in 1489 patients with acute ischemic stroke (<48 hr) with admission BP of | 5.14 | The relationship between baseline blood pressure and computed tomography findings in acute stroke: data from the tinzaparin in acute ischaemic stroke trial (TAIST). ( Bath, PM; Christensen, H; De Deyn, PP; England, T; Geeganage, C; Gray, LJ; Leys, D; Moulin, T; O'Neill, D; Ringelstein, EB; Sare, GM; Woimant, F, 2009) |
| "TAIST was a randomized, controlled trial assessing the safety and efficacy of tinzaparin versus aspirin in 1484 patients with acute ischemic stroke." | 5.12 | Sex differences in quality of life in stroke survivors: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST). ( Bath, PM; Boysen, G; De Deyn, PP; Gray, LJ; Leys, D; O'Neill, D; Ringelstein, EB; Sprigg, N, 2007) |
| "Heparin in Acute Embolic Stroke Trial (HAEST) was a multicentre, randomised, double-blind, and double-dummy trial on the effect of low-molecular-weight heparin (LMWH, dalteparin 100 IU/kg subcutaneously twice a day) or aspirin (160 mg every day) for the treatment of 449 patients with acute ischaemic stroke and atrial fibrillation." | 5.09 | Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000) |
| "The results show that the treatment with heparin and nadroparin is safe and effective." | 2.82 | The safety and efficacy of Heparin and Nadroparin compared to placebo in acute ischemic stroke - pilot study. ( Dluha, J; Dusenka, R; Kalmarova, K; Kantorova, E; Kurca, E; Nosal, V; Sivak, S; Turcanova Koprusakova, M, 2016) |
| "Internal carotid artery stenosis was asymptomatic in 55% and symptomatic in 45%." | 2.73 | Safety and efficacy of intravenous enoxaparin for carotid endarterectomy: a prospective randomized pilot trial. ( Assadian, A; Hagmüller, GW; Hübl, W; Klingler, A; Knöbl, P; Pfaffelmeyer, N; Senekowitsch, C, 2008) |
| "Acute cerebral ischemia was discovered to be the most common cerebrovascular disease associated with SARS-CoV-2." | 1.72 | Coexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies? ( Ates, O; Dogan, M; Ersoz, E; Hacioglu Kasim, FB; Karaarslan, N; Ozbek, H; Yilmaz, I, 2022) |
| "Delayed cerebral ischemia (DCI) is one of the major causes of delayed morbidity and mortality in patients with aneurysmal subarachnoid hemorrhage (aSAH)." | 1.48 | High-Dose Nadroparin Following Endovascular Aneurysm Treatment Benefits Outcome After Aneurysmal Subarachnoid Hemorrhage. ( Berg, RVD; Coert, BA; Post, R; Vandertop, WP; Verbaan, D; Zijlstra, IAJ, 2018) |
| "Perfusion of the cerebral blood flow in patients with cerebral vascular insufficiency was studied using perfusion computed tomography before and after monotherapy with fraxiparine (single dosage 0." | 1.35 | [The effect of fraxiparine on the tomographic parameters of cerebral perfusion in young patients with cerebral vascular insufficiency]. ( El'chaninov, AP; Kuznetsov, SV, 2008) |
| "Focal cerebral ischemia was induced by the intraluminal suture, middle cerebral artery occlusion (MCAO) method." | 1.32 | The low molecular weight heparin enoxaparin reduces infarct size in a rat model of temporary focal ischemia. ( Jonas, S; Li, YS; Quartermain, D, 2003) |
| " Fewer total adverse events were noted in the LMWH group than in the IVUH cohort (3 versus 20; P:=0." | 1.31 | Safety and cost of low-molecular-weight heparin as bridging anticoagulant therapy in subacute cerebral ischemia. ( Gandhi, R; Kalafut, MA; Kidwell, CS; Saver, JL, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (12.00) | 18.2507 |
| 2000's | 22 (44.00) | 29.6817 |
| 2010's | 19 (38.00) | 24.3611 |
| 2020's | 3 (6.00) | 2.80 |
| Authors | Studies |
|---|---|
| Post, R | 1 |
| Zijlstra, IAJ | 1 |
| Berg, RVD | 1 |
| Coert, BA | 1 |
| Verbaan, D | 1 |
| Vandertop, WP | 1 |
| Dluha, J | 1 |
| Sivak, S | 1 |
| Kurca, E | 1 |
| Dusenka, R | 1 |
| Kalmarova, K | 1 |
| Turcanova Koprusakova, M | 1 |
| Kantorova, E | 1 |
| Nosal, V | 1 |
| El'chaninov, AP | 1 |
| Kuznetsov, SV | 1 |
| Bang, OY | 1 |
| Kim, JS | 1 |
| Wang, QS | 1 |
| Chen, C | 2 |
| Chen, XY | 1 |
| Han, JH | 1 |
| Soo, Y | 1 |
| Leung, TW | 1 |
| Mok, V | 1 |
| Wong, KS | 5 |
| Bellido, M | 1 |
| van der Velden, VH | 1 |
| Leebeek, FW | 1 |
| te Boekhorst, PA | 1 |
| Hartung, O | 1 |
| Miranda, E | 1 |
| Alimi, YS | 1 |
| Juhan, C | 1 |
| Sarma, GR | 1 |
| Roy, AK | 1 |
| Kumar, S | 1 |
| Ng, PW | 1 |
| Tsoi, TH | 2 |
| Li, HL | 1 |
| Fong, WC | 1 |
| Yeung, J | 1 |
| Wong, CK | 1 |
| Yip, KK | 1 |
| Gao, H | 1 |
| Wong, HB | 1 |
| Kay, R | 3 |
| Yu, YL | 1 |
| Chan, YW | 1 |
| Ahuja, AT | 1 |
| Chan, FL | 1 |
| Fong, KY | 1 |
| Law, CB | 1 |
| Wong, A | 1 |
| Woo, J | 1 |
| Bloom, JM | 1 |
| Keskin, H | 1 |
| Keskin, F | 1 |
| Yildirim, E | 1 |
| Saritas, S | 1 |
| Polat, G | 1 |
| Colak, A | 1 |
| Laloglu, F | 1 |
| Guler, MA | 1 |
| Ozay, M | 1 |
| Alp, H | 1 |
| Ates, O | 1 |
| Yilmaz, I | 1 |
| Karaarslan, N | 1 |
| Ersoz, E | 1 |
| Hacioglu Kasim, FB | 1 |
| Dogan, M | 1 |
| Ozbek, H | 1 |
| Sierra-Hidalgo, F | 1 |
| Muñoz-Rivas, N | 1 |
| Torres Rubio, P | 1 |
| Chao, K | 1 |
| Villanova Martínez, M | 1 |
| Arranz García, P | 1 |
| Martínez-Acebes, E | 1 |
| Navi, BB | 1 |
| Marshall, RS | 1 |
| Bobrow, D | 1 |
| Singer, S | 1 |
| Stone, JB | 1 |
| DeSancho, MT | 1 |
| DeAngelis, LM | 1 |
| Martín Guerra, JM | 1 |
| Asenjo, MM | 1 |
| Dueñas Gutiérrez, CJ | 1 |
| Gil González, I | 1 |
| Loidi Pascual, L | 1 |
| Valcayo Peñalba, A | 1 |
| Yerani Ruiz de Azúa Ciria, A | 1 |
| Yanguas Bayona, I | 1 |
| Yi, X | 1 |
| Lin, J | 2 |
| Wang, C | 1 |
| Zhang, B | 1 |
| Chi, W | 1 |
| Squizzato, A | 1 |
| Lussana, F | 1 |
| Cattaneo, M | 1 |
| Sorrentino, D | 1 |
| Biehler, JL | 1 |
| Warman, R | 1 |
| Azab, SF | 1 |
| Akeel, NE | 1 |
| Abdalhady, MA | 1 |
| Elhewala, AA | 1 |
| Ali, ASA | 1 |
| Amin, EK | 1 |
| Sarhan, DT | 1 |
| Almalky, MAA | 1 |
| Elhindawy, EM | 1 |
| Salam, MMA | 1 |
| Soliman, AA | 1 |
| Abdellatif, SH | 1 |
| Ismail, SM | 1 |
| Elsamad, NA | 1 |
| Hashem, MIA | 1 |
| Aziz, KA | 1 |
| Elazouni, OMA | 1 |
| Arafat, MS | 1 |
| Fraint, E | 1 |
| Miller, R | 1 |
| Walter, A | 1 |
| Santos, M | 1 |
| Cruz, S | 1 |
| Casimiro, C | 1 |
| Biscoito, M | 1 |
| Costa, M | 1 |
| Kase, CS | 1 |
| Albers, GW | 1 |
| Bladin, C | 1 |
| Fieschi, C | 1 |
| Gabbai, AA | 1 |
| O'Riordan, W | 1 |
| Pineo, GF | 1 |
| Xu, L | 1 |
| Wang, J | 1 |
| Pan, J | 1 |
| Sun, L | 1 |
| Xia, Q | 1 |
| Luo, B | 1 |
| Pineo, G | 1 |
| Stern, L | 1 |
| Subrahmanian, T | 1 |
| Annemans, L | 1 |
| Turpie, AG | 2 |
| Hull, RD | 1 |
| Schellong, SM | 1 |
| Tapson, VF | 1 |
| Monreal, M | 1 |
| Samama, MM | 1 |
| Chen, M | 1 |
| Yusen, RD | 1 |
| Quartermain, D | 2 |
| Li, YS | 1 |
| Jonas, S | 3 |
| Wurm, G | 1 |
| Tomancok, B | 1 |
| Nussbaumer, K | 1 |
| Adelwöhrer, C | 1 |
| Holl, K | 1 |
| Assadian, A | 1 |
| Knöbl, P | 1 |
| Hübl, W | 1 |
| Senekowitsch, C | 1 |
| Klingler, A | 1 |
| Pfaffelmeyer, N | 1 |
| Hagmüller, GW | 1 |
| Sugimori, M | 1 |
| Llinás, R | 1 |
| Li, Y | 1 |
| Kalafut, MA | 1 |
| Gandhi, R | 1 |
| Kidwell, CS | 1 |
| Saver, JL | 1 |
| Gallus, AS | 1 |
| Cohen, AT | 1 |
| Alikhan, R | 1 |
| Stutzmann, JM | 1 |
| Mary, V | 1 |
| Wahl, F | 1 |
| Grosjean-Piot, O | 1 |
| Uzan, A | 1 |
| Pratt, J | 1 |
| Hillbom, M | 1 |
| Erilä, T | 1 |
| Sotaniemi, K | 1 |
| Tatlisumak, T | 1 |
| Sarna, S | 1 |
| Kaste, M | 1 |
| Counsell, C | 1 |
| Sandercock, P | 1 |
| Diener, HC | 1 |
| Ringelstein, EB | 5 |
| von Kummer, R | 1 |
| Langohr, HD | 1 |
| Bewermeyer, H | 1 |
| Landgraf, H | 1 |
| Hennerici, M | 1 |
| Welzel, D | 1 |
| Gräve, M | 1 |
| Brom, J | 1 |
| Weidinger, G | 1 |
| Hecking, C | 1 |
| Hendelmeier, M | 1 |
| von Bardeleben, R | 1 |
| Gröschel, K | 1 |
| Schinzel, H | 1 |
| Wade, WE | 1 |
| Berge, E | 1 |
| Abdelnoor, M | 1 |
| Nakstad, PH | 1 |
| Sandset, PM | 1 |
| Sare, GM | 1 |
| Bath, PM | 4 |
| Gray, LJ | 4 |
| Moulin, T | 1 |
| Woimant, F | 1 |
| England, T | 1 |
| Geeganage, C | 1 |
| Christensen, H | 2 |
| De Deyn, PP | 4 |
| Leys, D | 4 |
| O'Neill, D | 4 |
| Sprigg, N | 3 |
| Lindenstrøm, E | 1 |
| Boysen, G | 2 |
| Friis, P | 1 |
| Marttila, R | 1 |
| Olsson, JE | 1 |
| van der Sande, JJ | 1 |
| Masson, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine[NCT04507178] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-02-02 | Recruiting | ||
| Monitoring the Efficacy and Safety of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke[NCT01862978] | Phase 4 | 150 participants (Anticipated) | Interventional | 2013-05-31 | Recruiting | ||
| Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients With Embolic Stroke Due to Atrial Fibrillation[NCT02159287] | Phase 2 | 80 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| An Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in the Prevention of Venous Thromboembolism in Patients Following Acute Ischemic Stroke[NCT00077805] | Phase 4 | 0 participants | Interventional | 2003-08-31 | Completed | ||
| A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged Immobilization[NCT00077753] | Phase 4 | 4,726 participants | Interventional | 2002-02-28 | Completed | ||
| Pilot Study of Treatment With Intravenous Enoxaparin and/or Oral Minocycline to Limit Infarct Size After Ischemic Stroke[NCT00836355] | 6 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to Too few acute stroke patients available to meet enrollment requirements.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for dalteparin and Cerebral Ischemia
| Article | Year |
|---|---|
[Per and early postoperative use of low molecular weight heparin in carotid surgery].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Vessel Prosthesis Implantation; Brain Ischemia | 2003 |
Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Brain Ischemi | 2015 |
Preventing venous thromboembolism in general medical inpatients and after an ischaemic stroke.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Brain Ischemia; Cerebral Hemorrhage; Clinical Trials as | 2000 |
Prophylaxis of venous thromboembolism in medical patients.
Topics: Anticoagulants; Bandages; Brain Ischemia; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Myocard | 2001 |
Neuroprotective profile of enoxaparin, a low molecular weight heparin, in in vivo models of cerebral ischemia or traumatic brain injury in rats: a review.
Topics: Animals; Anticoagulants; Brain Edema; Brain Injuries; Brain Ischemia; Cognition Disorders; Enoxapari | 2002 |
Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischemic stroke (Cochrane review).
Topics: Acute Disease; Anticoagulants; Brain Ischemia; Chondroitin Sulfates; Databases, Factual; Dermatan Su | 2002 |
Cost-effectiveness of venous thrombosis prophylaxis following ischemic stroke: an assessment of currently available literature.
Topics: Brain Ischemia; Chondroitin Sulfates; Clinical Trials as Topic; Cost-Benefit Analysis; Dalteparin; D | 1998 |
19 trials available for dalteparin and Cerebral Ischemia
| Article | Year |
|---|---|
The safety and efficacy of Heparin and Nadroparin compared to placebo in acute ischemic stroke - pilot study.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Anticoagulants; Brain Ischemia; Double-Blind Met | 2016 |
Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arterial Occlusive Diseases; As | 2012 |
Nadroparin plus aspirin versus aspirin alone in the treatment of acute ischemic stroke.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Drug Therapy, Combination; Female; Humans; Injections, Subc | 2003 |
Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arterial Occlusive Diseases; A | 2007 |
Low-molecular-weight heparin for the treatment of acute ischemic stroke.
Topics: Activities of Daily Living; Acute Disease; Aged; Brain Ischemia; Cerebral Hemorrhage; Cerebral Infar | 1995 |
Pilot study of low-molecular-weight heparin in the treatment of acute ischemic stroke.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Brain Ischemia; Female; Humans; Male; Middle Aged; Na | 1994 |
Enoxaparin vs Aspirin in Patients With Cancer and Ischemic Stroke: The TEACH Pilot Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Enoxaparin; Female; Fibrinolyti | 2018 |
Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deterioration and improving six-month outcome.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Enoxaparin; Female; Humans; Male; | 2014 |
Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study.
Topics: Aged; Brain Ischemia; Enoxaparin; Female; Heparin; Humans; Male; Middle Aged; Stroke; Treatment Outc | 2009 |
Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study.
Topics: Aged; Brain Ischemia; Enoxaparin; Female; Heparin; Humans; Male; Middle Aged; Stroke; Treatment Outc | 2009 |
Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study.
Topics: Aged; Brain Ischemia; Enoxaparin; Female; Heparin; Humans; Male; Middle Aged; Stroke; Treatment Outc | 2009 |
Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study.
Topics: Aged; Brain Ischemia; Enoxaparin; Female; Heparin; Humans; Male; Middle Aged; Stroke; Treatment Outc | 2009 |
Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: results from the EXCLAIM study.
Topics: Aged; Brain Ischemia; Delayed-Action Preparations; Double-Blind Method; Enoxaparin; Female; Humans; | 2013 |
Reduction of ischemic sequelae following spontaneous subarachnoid hemorrhage: a double-blind, randomized comparison of enoxaparin versus placebo.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Brain Ischemia; Cerebral Infarction; Double-Blind Me | 2004 |
Safety and efficacy of intravenous enoxaparin for carotid endarterectomy: a prospective randomized pilot trial.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Loss, Surgical; Blood Transfusion; Brain Ische | 2008 |
Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anticoagulants; Asp | 2002 |
Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Brain Ischemia; Dose-Response Relationsh | 2001 |
Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; | 2000 |
The relationship between baseline blood pressure and computed tomography findings in acute stroke: data from the tinzaparin in acute ischaemic stroke trial (TAIST).
Topics: Acute Disease; Aspirin; Blood Pressure; Brain; Brain Ischemia; Causality; Cerebral Hemorrhage; Comor | 2009 |
Quality of life after ischemic stroke varies in western countries: data from the tinzaparin in Acute Ischaemic Stroke Trial (TAIST).
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Emotions; Europe; Female; | 2012 |
Stroke severity, early recovery and outcome are each related with clinical classification of stroke: data from the 'Tinzaparin in Acute Ischaemic Stroke Trial' (TAIST).
Topics: Aged; Aged, 80 and over; Brain Infarction; Brain Ischemia; Cerebral Hemorrhage; Disease Progression; | 2007 |
Sex differences in quality of life in stroke survivors: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST).
Topics: Activities of Daily Living; Age Factors; Aged; Aspirin; Brain Ischemia; Double-Blind Method; Female; | 2007 |
24 other studies available for dalteparin and Cerebral Ischemia
| Article | Year |
|---|---|
High-Dose Nadroparin Following Endovascular Aneurysm Treatment Benefits Outcome After Aneurysmal Subarachnoid Hemorrhage.
Topics: Adult; Aged; Aneurysm, Ruptured; Brain Ischemia; Embolization, Therapeutic; Endovascular Procedures; | 2018 |
[The effect of fraxiparine on the tomographic parameters of cerebral perfusion in young patients with cerebral vascular insufficiency].
Topics: Adult; Brain; Brain Ischemia; Cerebrovascular Circulation; Female; Fibrinolytic Agents; Humans; Male | 2008 |
Low-molecular-weight heparin in atherosclerotic stroke: a surprising resurrection of anticoagulants?
Topics: Antifibrinolytic Agents; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Female; Humans; Intra | 2012 |
Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: Is eculizumab indicated?
Topics: Adult; Anemia, Aplastic; Anticoagulants; Brain Ischemia; Cerebral Hemorrhage; Fatal Outcome; Hemoglo | 2012 |
Nadroparin in acute ischemic stroke.
Topics: Anticoagulants; Brain Ischemia; Humans; Nadroparin; Stroke | 2004 |
Low-molecular-weight heparin for the treatment of acute ischemic stroke.
Topics: Acute Disease; Aspirin; Brain Ischemia; Fibrinolytic Agents; Humans; Nadroparin; Platelet Aggregatio | 1996 |
Low-molecular-weight heparin and serum potassium.
Topics: Anticoagulants; Brain Ischemia; Cerebrovascular Disorders; Humans; Nadroparin; Potassium | 1997 |
Case of Venous Thromboembolia Under Enoxaparin Prophylaxis After Recovering From Acute Ischemic Stroke in Consequence of COVID-19-Related MIS-C.
Topics: Anticoagulants; Brain Ischemia; COVID-19; Enoxaparin; Humans; Ischemic Stroke; Systemic Inflammatory | 2022 |
Coexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies?
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clopidogrel; COVID-19; Enoxaparin; Humans; Manni | 2022 |
Large artery ischemic stroke in severe COVID-19.
Topics: Aged; Brain Ischemia; Cerebral Arteries; Computed Tomography Angiography; Coronavirus Infections; CO | 2020 |
Synchronous Cardiopulmonary Consequences of the Hypercoagulable State Associated With Cancer.
Topics: Adenocarcinoma; Anticoagulants; Brain Ischemia; Computed Tomography Angiography; Endocarditis, Non-I | 2019 |
[Bullous hemorrhagic dermatosis induced by heparin: description of 2 new cases].
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Drug Eruptions; Enoxaparin; Hemo | 2014 |
Pediatric Homonymous Superior Quadrantanopia in the Presence of Acute Vertebral Artery Dissection.
Topics: Brain Ischemia; Child; Enoxaparin; Hemianopsia; Humans; Magnetic Resonance Imaging; Male; Retrospect | 2015 |
Serum Hepcidin Levels in Childhood-Onset Ischemic Stroke: A Case-Control Study.
Topics: Acute Disease; Adolescent; Brain Ischemia; Child; Child, Preschool; Enoxaparin; Enzyme-Linked Immuno | 2016 |
Posterior Reversible Encephalopathy Syndrome and Cerebral Sinus Thrombosis in a Case of Pediatric B-Cell ALL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Ischemia; Cerebral Infarction; Child, Preschoo | 2017 |
[Vertebral artery dissection associated with MURCS syndrome].
Topics: 46, XX Disorders of Sex Development; Anticoagulants; Brain Ischemia; Congenital Abnormalities; Diplo | 2017 |
Effect of enoxaparin and aspirin on hemodynamic disturbances after global cerebral ischemia in rats.
Topics: Animals; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Enoxaparin; Hemodynam | 2010 |
Economic impact of enoxaparin after acute ischemic stroke based on PREVAIL.
Topics: Adolescent; Adult; Aged; Anticoagulants; Brain Ischemia; Child; Costs and Cost Analysis; Decision Ma | 2011 |
The low molecular weight heparin enoxaparin reduces infarct size in a rat model of temporary focal ischemia.
Topics: Animals; Anticoagulants; Brain Infarction; Brain Ischemia; Disease Models, Animal; Drug Administrati | 2003 |
Is low molecular weight heparin a neuroprotectant?
Topics: Animals; Brain Ischemia; Calcium; Cerebellum; Clinical Trials as Topic; Dendrites; Enoxaparin; Guine | 1997 |
Enoxaparin, a low molecular weight heparin decreases infarct size and improves sensorimotor function in a rat model of focal cerebral ischemia.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Enoxaparin; Injections, Subcutaneous; Male; Motor Acti | 2000 |
Safety and cost of low-molecular-weight heparin as bridging anticoagulant therapy in subacute cerebral ischemia.
Topics: Adult; Aged; Ambulatory Care; Anticoagulants; Brain Ischemia; Drug Administration Schedule; Drug The | 2000 |
Recurrent cerebral ischaemia in a pregnant woman with patent foramen ovale II° and thrombophilia.
Topics: Adult; Anticoagulants; Brain Ischemia; Dalteparin; Female; Foramen Ovale, Patent; Humans; Injections | 2014 |
[High or middle dose tinzaparin versus aspirin for the treatment of cerebral ischemic accident].
Topics: Aspirin; Brain Ischemia; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Tinzaparin | 2001 |